Search hospitals > Indiana > Indianapolis
Riley Hospital for Children
Claim this profileIndianapolis, Indiana 46202
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Recurrence
Conducts research for Lymphoma
Conducts research for Cystic Fibrosis
551 reported clinical trials
39 medical researchers
Summary
Riley Hospital for Children is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Leukemia, Tumors, Recurrence, Lymphoma, Cystic Fibrosis and other specialties. Riley Hospital for Children is involved with conducting 551 clinical trials across 734 conditions. There are 39 research doctors associated with this hospital, such as Sandeep Batra, MD, Brian Weiss, MD, Melissa Bear, and Linda DiMeglio, MD.Area of expertise
1Leukemia
Global LeaderStage II
Philadelphia chromosome positive
CD22 positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Sandeep Batra, MDRiley Hospital for Children6 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
57 reported clinical trials
105 drugs studied
Brian Weiss, MDCincinnati Children's Hospital Medical Center3 years of reported clinical research
Expert in Neuroblastoma
Studies Neurofibromatosis
23 reported clinical trials
44 drugs studied
Melissa BearRiley Hospital for Children8 years of reported clinical research
Studies Tumors
Studies Recurrence
14 reported clinical trials
26 drugs studied
Linda DiMeglio, MDIndiana University - Riley Hospital for Children1 year of reported clinical research
Studies Type 1 Diabetes
Studies Diabetes
9 reported clinical trials
17 drugs studied
Clinical Trials running at Riley Hospital for Children
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Leukemia
Osteosarcoma
Brain Tumor
Acute Leukemia
Lymphoma
Rhabdomyosarcoma
Lymphoblastic Leukemia-Lymphoma
Tumors
Stem Cell Transplantation
for Leukemia
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
Recruiting2 awards Phase 3
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Imatinib + Chemotherapy
for Acute Lymphoblastic Leukemia
This study is evaluating whether a combination of drugs may help treat patients with a specific type of leukemia.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Riley Hospital for Children?
Riley Hospital for Children is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Leukemia, Tumors, Recurrence, Lymphoma, Cystic Fibrosis and other specialties. Riley Hospital for Children is involved with conducting 551 clinical trials across 734 conditions. There are 39 research doctors associated with this hospital, such as Sandeep Batra, MD, Brian Weiss, MD, Melissa Bear, and Linda DiMeglio, MD.
Where is Riley Hospital for Children located?
Riley Hospital for Children at IU Health is situated at 705 Riley Hospital Dr, Indianapolis, IN 46202.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Riley Hospital for Children, contact their department at 888.531.3004 (Monday-Friday, 8am - 4:30pm) or via email at financialcounseling@iuhealth.org. They provide support through Medicaid, IU Health Financial Assistance, and other health coverage programs. Indiana residents receiving care through emergency services, direct physician admission, or hospital transfers may qualify for extra assistance based on financial hardship.
What insurance does Riley Hospital for Children accept?
Riley Hospital for Children accepts a wide range of insurance plans, including Medicaid, The Healthy Indiana Plan (HIP), Hoosier Healthwise (HHW), COBRA, and private insurance plans such as Aetna, Anthem PPO/HMO, Blue Cross and Blue Shield, CIGNA HealthCare PPO/HMO, Humana ChoiceCare, and UnitedHealthcare. They participate in most major health plans in Indiana. Patients are advised to review their health plan provider directory and consult with their insurance company to confirm coverage.
What awards or recognition has Riley Hospital for Children received?
Riley Hospital for Children, located in Indianapolis, Indiana, is celebrated for its outstanding pediatric care, ranking among the nation's top children's hospitals in all 10 pediatric specialties according to U.S. News & World Report. It is also designated as a Level I Children's Surgery Center by the American College of Surgeons, showcasing its capability to offer comprehensive surgical care for infants and children with complex conditions.